NEW YORK (Reuters) Oct 03 – Seniors who take aspirin daily are twice as likely to have late stage macular degeneration than those who never take aspirin, according to a European study.
The data do not show that aspirin causes vision loss. But the findings, published online September 13th in Ophthalmology, are of concern if aspirin somehow exacerbates macular degeneration, given how many seniors take it daily for heart disease.
“For people who have age-related macular degeneration, it probably isn’t wise to recommend taking aspirin,” said Dr. William Christen, from the Division of Preventive Medicine at Brigham and Women’s Hospital in Boston, who was not involved in the study.
Researchers led by Dr. Paulus de Jong at the Netherlands Institute for Neuroscience and Academic Medical Center collected health and lifestyle information from nearly 4,700 people over age 65. The study included Norwegian, Estonian, British, French, Italian, Greek and Spanish seniors.
Of the 839 people who took aspirin each day, 36 (4.3%) had an advanced form of the disease called wet macular degeneration.
In comparison, roughly 2% who took aspirin less frequently had wet macular degeneration.
The wet form, caused by leaking blood vessels in the eyes, leads to vision loss in the center of the eye’s field of vision. The dry form is more common and less severe, although people still suffer visual impairment.
The researchers found that aspirin use was not tied to the dry form, nor to earlier stages of the disease.
“I don’t think that’s surprising,” Dr. Christen told Reuters health. “I think the effects of aspirin may be different in the early stages of age-related macular degeneration than in the late stages.”
Dr. de Jong told Reuters Health there has been controversy over the link between cardiovascular disease and macular degeneration.
He wrote in an email that his team had analyzed as “meticulously as possible” whether cardiovascular disease might have influenced the results, and still found that aspirin users — regardless of their heart health — are at a greater risk of the more serious type of vision loss.
He disagrees with Dr. Christen, however. For people with cardiovascular disease who take aspirin to prevent the condition from worsening, the benefits of the drug outweigh the risks to visual health, he believes.
“A healthy eye with full visual capacities is of no use in a dead body,” he said.
Larger studies that follow people over time and document their aspirin use and vision will help resolve aspirin’s role in macular degeneration, Dr. de Jong added.
By Kerry Grens